References
  1. Kelly CA, Saravanan V, Nisar M, et al [2014] Rheumatoid arthritis-related interstitial lung disease: associations,prognostic factors and physiological and radiological characteristics-a large multicentre UK study. Rheumatology (Oxford) 53:1676-1682
  2. Hyldgaard C, Hilberg O, Pedersen AB, et al [2017] A population-based cohort study of rheumatoid arthritis associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700-1706
  3. Ferna’ndez-Dı’az C, Castaneda S, Melero-Gonza’ lez RB, et al [2020] Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology 59(12):3906-3916. https.//doi.org/10.1093/rheumatology/keaa621(PMID: 33068439)
  4. Juge PA, Crestani B, Dieude’ P [2020] Recent advances in rheumatoid arthritis-associated interstitial lung Disease. Curr Opin Pulm Med 26(5):477-486. https.//doi.org/10.1097/MCP.0000000000000710(PMID: 32701675)
  5. Englanda BR, Hershberger D [2020] Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol 32(3):255-263. https.//doi.org/10.1097/BOR.0000000000000703
  6. Cassone G, Manfredi A, Vacchi C, et al [2020] Treatment of rheumatoid arthritis-associated interstitial lung disease: lights and shadows. J Clin Med 9(4):1082. https.//doi.org/10.3390/jcm9041082
  7. Yang GX, Lyu L, Wang XH, et al [2019] Systemic treatment with resveratrol alleviates adjuvant arthritis-interstitial lung disease in rats via modulation of JAK/STAT/RANKL signaling pathway. Pulm Pharmacol Ther 56:69-74
  8. Montero P, Milara J, Roger I, et a l [2021] Role of JAK/STAT in Interstitial Lung Diseases,Molecular and Cellular Mechanisms. Int J Mol Sci 22(12):6211. https.//doi.org/10.3390/ijms22126211(PMID: 34207510)
  9. Vacchi G, Manfredi A, Cassone G, et al [2021] Tofacitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis.Case Rep Med 22, 2021:6652845
  10. Sendo S, Saegusa J, Yamada H, et al [2019] Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice. Arthritis Res Ther 21(1):184. https.//doi.org/ 10.1186/s13075-019-1963-2
  11. Lescoat A, Lelong M, Jeljeli M, et al [2020] Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol 178:114103. https.//doi.org/10.1016/j.bcp.2020.114103
  12. Atardella M, Di Carlo M, Carotti M, et al [2022] Retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease. Inflammopharmacology 30(3):705-712. https.//doi.org/ 10.1007/s10787-022-00936-w
  13. Zhao L, Mu BY, Zhou RW, et al [2019] Iguratimod ameliorates bleomycin induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9. Int. J. Rheum. Dis 22 (4) 686-694
  14. Jiang H, Gao H, Wang Q, et al [2020] Molecular mechanisms and clinical application of Iguratimod: A review. Biomed Pharmacother 122: 109704
  15. Han Q, Zheng ZH, Liang Q,et al [2021] Iguratimod reduces B-cell secretion of immunoglobulin to play a protective role in interstitial lung disease.Int Immunopharmacol 97(8):107596. https.//doi.org/10.1016/j.intimp.2021.107596.)
  16. Fujikia Y, Kotania T, Isodab K, et al [2018] Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. MODERN RHEUMATOLOGY 28(1):133-140. https.//doi.org/10.1080/14397595.2017.1318468
  17. Kodera K, Tsutsumi T, Oka Y, et al [2021]Two cases of rheumatoid arthritis complicated by organising pneumonia successfully treated with tofacitinib therapy. Mod Rheumatol Case Rep 5(2):218-225. https.//doi.org/10.1080/24725625.2021.1899372
  18. Vacchi G, Manfredi A, Cassone G, et al [2021] Tofacitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis.Case Rep Med 22, 2021:6652845
  19. Tanaka Y, Maeshima K, Yamaoka K [2012] In vitro and in vivo analysis of JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 71(Suppl 2):i70-174. https.//doi.org/10.1136/annrheumdis-2011-200595
  20. Wang WX, Bhattacharyya S, Marangoni RG, et al [2020] The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord 5(1):40-50. https.//doi.org/ 10.1177/2397198319865367.
  21. Kurasawa K, Arai S, Namiki Y, et al [2018] Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57(12):2114-2119
  22. Wu YX, Sun Y, Ye YP, et al [2017] Iguratimod prevents ovariectomy induced bone loss and suppresses osteoclast ogenesis via inhibition of peroxisome proliferator activated receptor gamma. Mol. Med. Rep 16 (6) 8200-8208